Navigation Links
Flexion's Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
Date:5/30/2012

WOBURN, Mass., May 30, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that its lead osteoarthritis drug candidate, FX005, demonstrated significant pain relief over placebo at four weeks* in a Phase 2 proof-of-concept trial. Top-line data showed FX005, delivered intra-articularly to the knee, was well-tolerated and resulted in prolonged improvement in joint pain and function throughout the 12-week duration of the study. These are the first-ever clinical results demonstrating the efficacy of a p38 MAP kinase inhibitor in osteoarthritis patients. Flexion plans to present the complete data set and analyses at an upcoming medical conference.

"There is considerable unmet need for treatments for the pain and damage caused by osteoarthritis," said Timothy McAlindon, chair of rheumatology and professor of medicine at Tufts Medical Center. "In particular, physicians and patients need targeted treatments for osteoarthritis that are more effective and longer lasting. These results represent a significant advance in that direction, so we will eagerly monitor development of this new treatment."

Michael Clayman, M.D., chief executive officer of Flexion, said, "We believe these data not only demonstrate the therapeutic potential of FX005 but also validate Flexion's approach to the treatment of osteoarthritis -- intra-articular delivery of sustained-release therapies providing prolonged activity at the site of disease while minimizing systemic exposure and the corresponding risk of systemic side effects. We are enthusiastic about advancing FX005 into the next phase of clinical development, which will be a Phase 2b dose-ranging study that we plan to initiate in the first half of 2013. The data from that study will then be used to identify an optimal dose for Phase 3."

The trial was a double-blind, placebo-controlled study in which 104 patients were randomized to receive FX005 or placebo via int
'/>"/>

SOURCE Flexion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee
2. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
3. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the OARSI 2007 World Congress on Osteoarthritis
4. Osteoarthritis: Which Treatments Work and Which Dont?
5. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
6. Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis
7. Interleukin Genetics to Present Important New Findings at 2008 World Congress on Osteoarthritis
8. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
11. New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Korea , Aug. 28, 2015 ... University and Dr. Ra from Biostar , Published ... Confirmed 30% increase of lifespan through multiple IV administration ... physical vitality, and life expectancy found , Commercialization ... Korea have determined the possibility that adult mesenchymal stem ...
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... 27, 2015 According to a new market ... Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type ... published by MarketsandMarkets, the Medical Lifting Sling Market is poised to ... 2015, at a CAGR of 11.4 % from 2015 to 2020. ... rket data T ables and 65 ...
Breaking Medicine Technology:Korean Researchers Find the Possibility that Adult Mesenchymal Stem Cells (MSCs) May Extend Lifespan 2AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... ITMN ) today announced that Dan Welch, Chairman, Chief ... Fourth Annual JMP Securities Healthcare Focus Conference in New York ... , To access a live audio webcast of the presentation, ... investor relations page of InterMune,s corporate website at www.intermune.com. ...
... Pharmaceutical Company Limited (Osaka, Japan, "Takeda") announced today ... Mexico, Turkey, Sweden, Norway, Denmark, Belgium and Luxembourg. ... de C.V., Takeda Pharmaceuticals Trade, LLP (Turkey), Takeda ... SPRL (Belgium) - are part of Takeda,s strategic ...
Cached Medicine Technology:Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe 2Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe 3
(Date:8/30/2015)... ... August 30, 2015 , ... Scientists in France say asbestos exposure may put ... cancers. Surviving Mesothelioma has just posted an article on the new research. Click ... the cancer incidence among 2,024 French asbestos plant workers from 1978 to 2009. In ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... promoted from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional ... professional, focused on your goals. Kathleen graduated from Florida State University with ...
(Date:8/29/2015)... ... ... On Saturday, September 19, 2015, Diane Blackburn-Zambetti, the Director of Policy and Prevention ... educational program titled “Asbestos and Your Health.” , The two and one half hour ... at Calvary United Methodist Church, 16 E Park Ave., Ambler, PA 19002. , This ...
(Date:8/29/2015)... ... 2015 , ... Brands like Toppik , Eau Thermale Avene and Bliss ... a threshold of $49.00 was required to qualify for free standard shipping,” said Jennifer ... shipping for customers regardless of the item’s selling price.” , With competitive pricing in ...
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
Breaking Medicine News(10 mins):Health News:Researchers Say Mesothelioma Not the Only Cancer Linked with Asbestos Exposure, According to Surviving Mesothelioma 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2
... A new drug cocktail might be the right mix ... standard therapy. Details of a new study supporting this ... treatments to work again. The findings were presented today ... The study involves post-menopausal women whose advanced breast cancers ...
... media are invited to attend a press availability period at ... scientific meeting evaluating the safety of soy infant formula. An ... research on soy infant formula to determine whether exposure to ... expert panel will also indentify data gaps and research needs. ...
... Technique might work with many other viruses, researchers say ... they,ve shown that human stem cells can be turned ... virus that causes AIDS. , Potentially, they say, the ... demonstrated in this proof-of-principle study that this type of ...
... vaccines, safety monitoring and improved federal coordination , ... better coordination are needed to develop vaccines for serious ... U.S. report says. , The report, from the Institute ... Plan. It cites a need to speed up development ...
... , PHILADELPHIA, Dec. 11 The Visiting ... home health and specialty services to patients who reside in ... offer include rehabilitative therapies, mental health services, wound and ostomy ... and social workers will provide these services to patients in ...
... , , , WINSTON-SALEM, N.C., Dec. 11 ... officers once again put the spotlight on mass murder in ... killings at Fort Hood, the Washington case raised questions about ... rampage. , Andrew Smiler, an assistant professor of psychology at ...
Cached Medicine News:Health News:Clinical trial advances new approach to re-sensitizing breast cancer 2Health News:Scientific panel evaluates soy infant formula safety 2Health News:Better Vaccine Planning Needed, Committee Finds 2Health News:Better Vaccine Planning Needed, Committee Finds 3Health News:The Visiting Nurse Association of Greater Philadelphia Expands Service to Bucks County 2Health News:Mass Murderers: Why Do They Kill? 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: